Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
15 oct. 2024 08h00 HE | Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
12 sept. 2024 16h05 HE | Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29 août 2024 08h00 HE | Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering-logo (1).png
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
06 août 2024 16h05 HE | Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31 juil. 2024 16h05 HE | Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering-logo (1).png
Immuneering to Present at the Jefferies Global Healthcare Conference
29 mai 2024 16h05 HE | Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering-logo (1).png
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07 mai 2024 16h05 HE | Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE | Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Immuneering-logo (1).png
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09 avr. 2024 12h00 HE | Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering-logo (1).png
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 16h05 HE | Immuneering Corporation
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference